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Hydrogels have become very popular due to their unique properties such as high water
content, softness, ﬂexibility and biocompatibility. Natural and synthetic hydrophilic poly-
mers can be physically or chemically cross-linked in order to produce hydrogels. Their
resemblance to living tissue opens up many opportunities for applications in biomedical
areas. Currently, hydrogels are used for manufacturing contact lenses, hygiene products,
tissue engineering scaffolds, drug delivery systems and wound dressings. This review pro-
vides an analysis of their main characteristics and biomedical applications. From Wich-
terle’s pioneering work to the most recent hydrogel-based inventions and products on
the market, it provides the reader with a detailed introduction to the topic and perspective
on further potential developments.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
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Hydrogels are three-dimensional, hydrophilic, poly-
meric networks capable of absorbing large amounts of
water or biological ﬂuids. Due to their high water content,porosity and soft consistency, they closely simulate natural
living tissue, more so than any other class of synthetic bio-
materials. Hydrogels may be chemically stable or they may
degrade and eventually disintegrate and dissolve [1].
Hydrogels are called ‘reversible’ or ‘physical’ gels if
molecular entanglements and/or secondary forces such as
ionic, H-bonding or hydrophobic forces play the main role
in forming the network. Physical gels are often reversible
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mental conditions, such as pH, and the ionic strength of
solution or temperature. In ‘permanent’ or ‘chemical’ gels,
the network of covalent bonds joining different macromo-
lecular chains can be achieved by cross-linking polymers in
the dry state or in solution [2]. These gels may be charged
or non-charged depending on the nature of functional
groups present in their structure. The charged hydrogels
usually exhibit changes in swelling upon variations in
pH, and it is known that they can undergo changes in shape
when exposed to an electric ﬁeld [3].
Chemical hydrogels are commonly prepared in two dif-
ferent ways: ‘three-dimensional polymerization’ (Fig. 1), in
which a hydrophilic monomer is polymerized in the pres-
ence of a polyfunctional cross-linking agent, or by direct
cross-linking of water-soluble polymers (Fig. 2). Polymeri-
zation is usually initiated by free-radical generating com-
pounds such as benzoyl peroxide, 2,2-azo-isobutyronitrile
(AIBN), and ammonium peroxodisulphate or by using
UV-, gamma- or electron beam-radiation. However,
three-dimensional polymerization often results in materi-
als containing signiﬁcant levels of residual monomers
and therefore puriﬁcation of these materials has to be per-
formed thoroughly because the unreacted monomers are
often toxic and could leach out from the hydrogels contin-
uously. The puriﬁcation of hydrogels containing residual
monomers is typically performed by extraction into excess
water, and can take up to several weeks to be completed
[4–7].
There are numerous approaches that could be used to
improve or avoid the puriﬁcation process. One possibility
is the use of additional processes that lead to the highestFig. 1. Synthesis of hydrogels by threpossible degrees of monomer conversion, which could be
achieved by conducting three-dimensional polymerization
followed by subsequent post-polymerization curing (e.g.
by thermal treatment or irradiation of the resulting prod-
ucts) [8,9]. Alternatively, the selection of non-toxic mono-
mers used for the three-dimensional polymerization, such
as oligomers or macromonomers (e.g. polyethylene glycol
dimethacrylate) could be a solution [10].
It is also possible to avoid the need for puriﬁcation of
hydrogels after their synthesis by cross-linking ready-
made water-soluble polymers. Water-soluble polymers
such as poly(acrylic acid), poly(vinyl alcohol), poly(vinyl-
pyrrolidone), poly(ethylene glycol), polyacrylamide and
some polysaccharides are the most common systems used
to form hydrogels. These water-soluble polymers are non-
toxic and widely used in various pharmaceutical and bio-
medical applications and therefore do not require removal
from the system, eliminating the need for a puriﬁcation
step. Radiation induced cross-linking, such as of an aque-
ous solution of hydrophilic polymers with gamma rays,
allows simultaneous formation of a hydrogel and its steril-
ization. Rosiak et al. [11,12] used cross-linking of natural
polymers (such as gelatine or agar) and synthetic polymers
(such as poly(vinyl pyrrolidone) (PVP) or poly(vinyl alco-
hol) (PVA) which were cross-linked by gamma radiation
for the production of sterile hydrogels used in wound care.
Currently their hydrogels are manufactured and marketed
as ‘Kikgel’ and ‘Aqua-gel’ wound dressings [11,12].
Recently, Khutoryanskiy et al. [4,13] reported an alter-
native method to synthesise hydrogels from ready-made
water-soluble polymers in aqueous solutions using ther-
mal treatment or microwave irradiation. In this methode-dimensional polymerization.
Fig. 2. Synthesis of hydrogels by cross-linking of ready-made water-soluble polymers.
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such as poly(methyl vinyl ether-alt-maleic anhydride)
and poly(vinyl alcohol) are mixed together at room tem-
perature and the cross-linking process is achieved by ther-
mal treatment under high pressure via autoclaving or
microwave radiation. Both radiation and thermal cross-
linking methods are inexpensive, safe, do not require a
puriﬁcation step and result in sterile hydrogels if a suitable
combination of hydrophilic polymers is used.
There are numerous original papers, academic reviews
and monographs focused on the synthesis, properties and
applications of hydrogels [1,3,14–22]. This review will con-
sider mostly patent literature on ‘chemical’ hydrogels and
their potential commercial applications in biomedical
areas. As shown by the considerable number of patents
and commercial products, the main areas of hydrogel
applications are contact lenses, wound dressings, drug
delivery systems, tissue engineering, and hygiene prod-
ucts; these will be covered in this review.
2. Contact lenses
In their pioneering 1960 paper, Wichterle and Lim were
the ﬁrst to describe a hydrogel based on poly-2-hydroxy-
ethylmethacrylate (PHEMA) as a synthetic biocompatible
material useful for contact lens applications [23]. PHEMA
lenses were distributed ﬁrstly in western Europe in 1962,
but with limited success. In 1965 the National Patent
Development Corporation (NPDC) bought the licence to
this technology. This was then sold to Bausch & Lomb,
which optimised Wichterle’s spin-casting process and
ﬁnally acquired the approval from the Food and Drug
Administration (FDA) for their PHEMA lenses in 1971 [24].
Contact lenses are mainly classiﬁed as ‘hard’ or ‘soft’
according to their elasticity. Even though hard lenses are
longer lasting, they tend to be poorly accepted by the
wearers and can require a lengthier adaptation period.
Hard contact lenses are primarily based on hydrophobic
materials such as poly(methyl methacrylate) (PMMA) orpoly(hexa-ﬂuoroisopropyl methacrylate) (HFIM), whereas
soft lenses are based on hydrogels [25].
Soft contact lenses can be produced with different tech-
niques, such as spin-casting, mold-casting and lathe-cut-
ting. In spin- and mold-casting a small amount of liquid
monomer mixture is placed into special ‘concave’ optical
molds in order to shape the lens. During spin-casting the
concave mold rotates to form the lens, causing the liquid
monomer to ﬂow out uniformly, coating the whole surface.
At the same time, polymerization of the monomer is car-
ried out at elevated temperatures, and the residual mono-
mer is carefully removed at the end of the process. The
mold-casting technique employs a convex mold which is
inserted into the liquid monomer which already contains
a mated concave mold, to make the back surface of the
lens. The polymerization takes place in the same way as
for the spin-casting. This process produces hard lens inter-
posed between the optical surfaces of the two different
molds and once the lens is dry it remains concave [26].
Innovative molds, useful for cast molding silicone hydrogel
contact lenses, have been described in the US Patent
6,861,123 B2 assigned to Johnson & Johnson Vision Care
Inc. Turner et al. [27] patented their polyoleﬁn inserts for
producing the molds and the method in which these are
used to make lenses. The preferred method for producing
the aforementioned lenses was by direct molding of the sil-
icone hydrogels, placing the reaction mixture in a mold
having the shape of the ﬁnal desired product, and then pro-
ceeding with the polymerization.
An alternative method used in the contact lens industry
is lathe-cutting (Fig. 3), in which the lenses are formed
from solid ‘buttons’ of dehydrated material. The liquid
monomer mixtures are usually bulk-polymerized in water
tanks for some period of time. This type of polymerization
is typically started using free-radical initiators which are
then decomposed by an increase in temperature. This pro-
cess results in the formation of longer polymer chains
(with higher molecular weights) and potentially more
chain entanglements. Oxygen-mediated degradation could
Fig. 3. Scheme of lathe-cutting technique.
Table 1
Requirements to the hydrogels used for contact lens applications.
Characteristics Requirements References
Luminous transmittance The minimum luminous transmittance value for contact lenses is 95%. This value signiﬁcantly affects the
transparency of the lens. A slit lamp microscope is typically used to observe any deposit (proteins, lipids,
bacteria, minerals) that may cause a lack of the usual transparency of the lens
[28,29]
Refractive index The refractive index of the human cornea surface may vary. Ideal hydrogels should have a refractive index
value matching the range 1.372–1.381
[30,31]
Sufﬁcient oxygen-
permeability
The oxygen permeability of the lens is directly proportional to water content and inversely to thickness. In
the contact lens industry the oxygen permeability is expressed as Dk. In order to prevent anoxia
throughout the cornea the oxygen transmissibility of the lens (Dk/t, where ‘t’ is the thickness of the lens)
required to be 35 for the open eye and 125 for the closed eye
[32–34]
Wettability and
permeability to water
The water-permeability of the lens is strictly related to thickness. A constant water diffusion rate is
normally reached within the ﬁrst hour of the experimental analysis. It directly depends on the wettability
of the lens, which is evaluated by advancing contact angle (Hw/a) measurements. The initial value for
hydrogel contact lens is usually around 25
[35,36]
Stability The stability of the material used affects the shelf-life and the manufacturing process of the lens [37]
Excellent mechanical
properties
The mechanical properties of the lens, such as the elastic modulus (E), have a great impact on their
adhesion to the corneal epithelium and on the comfort for the wearer
[38]
biocompatibility The biocompatibility of the material is essential for the ocular health of wearers who tend to use the lenses
for an extended period of time
[39]
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high volume to surface ratio, so it is possible to remove
the surfaces during the lathing process. The lenses are
ﬁnally collected from the centre of a button [24].
A polymeric hydrogel should have some important
physical properties to be used as a contact lens material
[24]. The ideal characteristics are listed in Table 1:
The equilibrium water content (EWC) of a hydrogel is
deﬁned as:
EWC ¼ m=mtot  100% ð1Þ
where m is the weight of water in polymer and mtot is the
total weight of hydrated polymer.EWC could change with temperature, pH and osmolal-
ity. For example, PHEMA contact lenses contain approxi-
mately 38–40% of water in the fully hydrated state. They
typically show low variability with changes in external fac-
tors [24].
In US Patent 3,679,504 [40], Wichterle disclosed a
method of forming colored soft contact lenses and ophthal-
mic prostheses. The colored ingredient was incorporated
between two transparent hydrogel layers bound together
by polymerizing the hydrophilic monomers mixture. The
covering hydrogel layer could also be made from a solution
of a hydrophilic macromonomer such as polyethylene gly-
col mono-methacrylate, which could be manufactured as
256 E. Caló, V.V. Khutoryanskiy / European Polymer Journal 65 (2015) 252–267described in US Patent 3,575,946 [41]. The use of
macromonomers for preparation of hydrogels can poten-
tially eliminate the need for their puriﬁcation as these
materials are often non-toxic [40].
In US Patent 4,472,327 [42] Neefe proposed a method of
making cosmetic hydrogel contact lenses which modiﬁed
the apparent color of the iris by using small light reﬂecting
particles imbedded in a colored transparent matrix. The
lenses described in this patent are of a dual purpose: to
correct the visual defects and to change the apparent color
of the eye. The whole lens area was transparent, providing
peripheral vision and allowing the natural iris pattern to be
visible through them. Neefe discovered that when a small
amount of high refractive index ﬁne particles was placed
in a matrix of transparent lens material of a substantially
lower refractive index, the reﬂected light had the color of
the lower refractive index media [42]. Selected particulate
material had been employed in the polymerization of
HEMA with benzoyl peroxide as an initiator. Furthermore,
it was possible to add a selected antimicrobial agent,
for example 3-(trimethoxysilyl)propyloctadecylmethyl
ammonium chloride, to the liquid monomer mixture
before polymerization to ensure that the resulting lenses
were more resistant to microbial growth [24].
Numerous attempts have been made to develop new
contact lenses with better physical and chemical proper-
ties. For instance, Jay Kunzer and Friends [43] disclosed
that certain hydrophobic monomers, such as those shown
in Fig. 4, can act as strengthening agents when copolymer-
ized with hydrophilic monomers such as HEMA, or
N-vinyl-2-pyrrolidone (NVP).
The soft contact lenses made from these monomers
combined with HEMA or NVP are large enough to cover
the whole cornea and present good oxygen permeability,
ensuring more comfort for wearers [43].Fig. 4. Some of the hydrophobic monomers used by Kunzer et al. [43].Lai and Quinn [44] proposed the use of a new class of
optically clear silicone thermoplastic hydrogel materials
in the production of contact lenses. The general formula
of the polymers, which includes a silicone-containing seg-
ment derived from polysiloxane linked with hydroxyl or
amino groups, is shown in Fig. 5.
These materials offered good physical strength and
excellent oxygen permeability. A drawback of ‘soft’ contact
lenses in general is their relatively poor gas permeability
resulting in oxygen deprivation of the cornea, which
receives oxygen only from the atmosphere. In the contact
lens industry oxygen permeability is deﬁned as ‘Dk’, where
‘D’ is the diffusivity of the lens and ‘k’ is the oxygen solubil-
ity in the lens material [24]. Dk essentially depends on
EWC in conventional hydrogels because oxygen has the
capability to diffuse through water rather than through
the gel. The relationship between these two parameters is:
Dk ¼ 1:67e0:0397EWC ð2Þ
where ‘e’ is the base of the natural logarithm. Oxygen
transmissibility of contact lenses may be calculated from
the Dk of the material divided by the lens thickness (t).
The units of Dk are called Fatt units (named after Professor
Irving Fatt) or Barrer [24]:
DkðbarrerÞ ¼ 1011ðcm2 mLO2Þ=secmLmmHg ð3Þ
Dk=t Dkðbarrer=cmÞ ¼ 109ðcmmLO2Þ=secmLmmHg
ð4Þ
Nowadays, silicone hydrogel (SiHy) lenses have become
prevalent on the market (Fig. 6), due to their higher oxygen
permeability and comfortable ﬁt [45].
One of the drawbacks associated with the use of SiHy
lenses is that they often undergo more protein deposition
than conventional lenses which leads to problems with
lens spoilage. In European Patent EP 2 365 360 A2, a
method for reducing protein deposition on contact lenses
has been proposed by adding protein uptake-reducing
compounds, such as butylated hydroxytoluene (BHT) or
hydroxyamines in the reaction mixture [46]. The reaction
mixture may include a ‘silicone-containing monomer’,
described in the US Patent 3,808,178 (Fig. 7) [47].
Contact lens surfaces should also have excellent wetta-
bility in order to avoid tear-ﬁlm deposits [47]. The SiHy
lenses have been made to compensate the hydrophobicity
of silicone and to improve its wettability. The silicone
hydrogel lenses were molded and plasma-treated after-
wards [49]. The clinical performance of any contact lens
material depends on its ability to produce a stable pre-
and post-lens tear ﬁlm, which is dependent on its wettabil-
ity. This can be described as the formation of a continuous
superﬁcial ﬂuid ﬁlm over a solid surface. The wettability
index is usually determined by measuring the contact
angle (a) of water on a lens surface. If a = 0 then water
is able to fully wet the lens, if a < 90 water wets the lens
and if a > 90 the lens is practically not wettable [48].
‘Soft’ lenses with greater adherence to the eye have
been developed in order to enhance the ﬁt, but on the
other hand, they have poor gas permeability and often do
not allow oxygen to reach the cornea at a sufﬁcient rate.
Fig. 5. General formula of the thermoplastic silicone-containing compositions employed by Lai et al. ‘M’ is a hydrophilic group; ‘R’ is an alkyl group with 1–
10 carbon atoms that can be separated by ether, urethane or ureido linkages; ‘R1’ is hydrogen, monovalent hydrocarbon groups or halogen substituted
monovalent hydrocarbon moieties with 1–18 carbon atoms; ‘Z’ may be a divalent urethane or ureido portion; ‘x’ and ‘y’ are equal or greater than 1 [44].
Fig. 6. Materials used in contact lenses manufacturing in 2012. Data for this ﬁgure was taken from [45]. Reprinted with permission from Contact Lens
Spectrum, published in January 2013. Contact Lens Spectrum is published monthly by PentaVision LLC 2014 All Rights Reserved. PentaVision is located at
321 Norristown Road, Suite 150, Ambler, PA 19002 (USA). Please visit www.contactlensspectrum.com for more information.
Fig. 7. General formula of polysiloxanylalkyl ester monomer presented in US Patent 3,808,178. A, X and Y can be C1–C5 alkyl groups or phenyl groups; R is a
methyl group or hydrogen; m is an integer from 1 to 5 and n is from 1 to 3 [47].
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problem, because they are composed of hydrated, cross-
linked polymeric material that contains silicon and a cer-
tain amount of water within the polymer matrix. More
recently, Bauman et al. [50] disclosed a method for making
SiHy contact lenses with a nano-textured surface, imitating
the surface of human cornea. The nano-textured surface
coating technique has been developed through controlled
soaking of the lens into a polymeric material, which can
comprise monomeric units of one or more carboxyl-con-
taining vinylic monomers. The nano-textures are then
ﬁxed by crosslinking a water-soluble hydrophilic poly-
meric material onto the prime coating.
One of the more recent products of the UK contact lens
industry is ‘Gentle 59’, promoted by Vista Optics Ltd. at the
European Federation of the Contact Lens and Iols Industries
Congress in Budapest in September 2012. Gentle 59 is
made of an acrylic acid-co-acrylamide hydrogel, which
seems to have very good tensile properties, moisture
retention characteristics and a very comfortable ﬁt [51].In addition to the applications of soft contact lenses in
correction of vision, they can potentially be used for drug
delivery to the eye. However, conventional hydrogel-based
contact lenses exhibit relatively low drug loading capacity
and often show a burst release upon ocular administration
[52]. Many methods have been developed to modify the
conventional contact lenses to improve their drug loading
and release. These include modifying the polymeric mate-
rials with a controlled hydrophilic/hydrophobic copolymer
ratio, impregnating drug-containing colloidal structures,
incorporating ligand-including hydrogels and developing
multilayered hydrogels [52]. Venkatesh et al. [53] showed
the potential of ‘biomimetic hydrogels’ as carriers to load
relevant amounts of H1-antihistamines. They also show
potential to release therapeutic dosages of drug in vitro
in a controlled manner for a period of 5 days, with a possi-
ble extension in the presence of proteins. Xu et al. [54]
incorporated b-cyclodextrin (b-CD) into hydrogels for con-
tact lenses, observing an increase in the equilibrium swell-
ing ratio and tensile strength. Puerarin was used as a
258 E. Caló, V.V. Khutoryanskiy / European Polymer Journal 65 (2015) 252–267model drug to study loading and release from PHEMA/
beta-CD hydrogels. It was established that puerarin load-
ing and the in vitro release rate depended on the amount
of beta-CD in the hydrogel. In rabbit eyes the PHEMA/
beta-CD hydrogel contact lenses demonstrated longer res-
idence time of puerarin in the tear ﬂuid compared to con-
ventional PHEMA contact lenses and 1% puerarin eye
drops.
Developing safe and cost-effective contact lenses is the
focus of the eye care industry. Contact lens materials with
optimal characteristics such as oxygen permeability, com-
fort, compliance, hygiene and disinfection have still not
been achieved, which opens exciting opportunities for fur-
ther developments in this area.3. Wound dressings
A wound is a defect or a break in the skin which can
result from trauma or medical/physiological conditions.
Wounds can be classiﬁed, depending on the number of skin
layers and on the area of the skin affected, as superﬁcial (if
only the epidermis is involved), partial-thickness (if the
epidermis and deeper dermal layers are affected) and
full-thickness wounds (when subcutaneous fat and deeper
tissue has been damaged) [55]. Wounds are usually sub-
divided into ‘acute’ or ‘chronic’ wounds. Chronic wounds
require dedicated nursing care that represents a signiﬁcant
cost for national health systems. Design of effective dress-
ings relies on an understanding of the healing process, as
well as the speciﬁc conditions of a patient and the effect
that each material used could have on the wound [55,56].
Wound healing can be hindered by various factors such as
desiccation, infection or abnormal bacterial presence, mac-
eration, necrosis, pressure, trauma and edema [57].Table 2
Advanced wound dressings (reprinted from P.S. Murphy, G.R.D. Evans,
Plastic Surgery International 2012, 2012, 1) [60].
Notes
Protective dressings
Gauze Inexpensive; readily available
Impregnated gauze Nonadherent; preserves moisture
Antimicrobial dressings
Antibacterial
ointments
Reapply often to maintain moisture
Iodine based Absorbent; Not for use with thyroid
disorders
Silver based Many forms; Broad spectrum; low
resistance
Autolytic debridement
Films Occlusive; allows exchange of gasses
Hydrocolloids Not for exudative or infected wounds
Hydrogels Rehydrates to soften dry wounds
Chemical debridement
Papain/urea Availability issues in US
Collagenase Selective debridement
Absorbent dressings
Foam Absorbs moderate exudate
Hydrogels Absorbs minimal exudate
Hydroﬁbers Absorbs heavy exudate
Alginates Absorbs heavy exudateThe ‘ideal’ wound management product should absorb
excess exudate and toxins, keep a good moisture between
the wound and the dressing, preserve the wound from
external sources of infection, prevent excess heat at the
wound, have good permeability to gases, be supplied com-
pletely sterile and be easy to remove without further
trauma to the wound [58].
Recently, the wound dressing industry highlighted the
importance of providing comfort and conformability of
dressings, the need for infrequent changes, cost effective-
ness and a long shelf life [58]. The choice of the right dress-
ing to suit a particular wound is therefore fundamental for
optimum healing and the quality of life of the patient [59].
The majority of the currently available products can be
classiﬁed as low adherent dressings, semipermeable ﬁlms,
hydrocolloids, hydrogels, alginates, foam dressings or anti-
microbial dressings [57]. Although plain gauze is still one
of the most commonly employed products in hospitals,
new wound dressing research and development has pro-
duced advanced materials with better physical and chem-
ical properties (Table 2). Gauze is certainly cheap, readily
available and suitable for a lot of wounds. In particular
the gauzes impregnated with some active ingredients such
as iodine, zinc oxide/zinc ions, or petrolatum show
enhanced performance. Iodine provides antimicrobial
properties, whereas zinc oxide could promote wound
cleansing and re-epithelialization [60,61]. However, the
use of gauze often results in problems associated with its
removal as it may cause trauma by stripping off newly
formed epidermis [62].
Advanced dressings are designed to maintain a moist
environment at the site of application, allowing the ﬂuids
to remain close to the wound but not spread to unaffected,
healthy skin areas [62]. The relevance of the moist wound
environment as a factor accelerating the healing process
was ﬁrst observed by Winter in 1962, but only recently
has received more serious attention [63]. Dressings
designed for moist wound healing are represented by
hydrogel and hydrocolloid products but only the latter
can absorb mild to medium exudate or drainage. Both
induce autolytic debridement, which facilitates the elimi-
nation of the dead tissue [57]. Hydrocolloids are usually
composed of sodium carboxymethylcellulose, gelatin, pec-
tin, elastomers and adhesives. Hydroﬁber(ConvaTec)
dressings allow moisture to be captured because they form
a swollen gel structure and conform to the wound site
forming a ‘seal’. Hydroﬁbermay be in the form of a hydro-
philic, non-woven ﬂat sheet dressing that can be converted
to a soft gel sheet by absorbing the wound exudate [58].
Hydrogels are widely used as debriding agents, moist
dressings, and components of pastes for wound care. How-
ever, they do not need further wound ﬂuids to become gels
and are suitable for dry wounds [60].
The so-called ‘moisture donor’ effect of hydrogels helps
autolytic debridement, increasing collagenase production
and the moisture content of necrotic wounds [62]. They
can absorb and retain contaminated exudate within the
gel mass through expansion of crosslinked polymer chains
resulting in isolation of bacteria, detritus and odour mole-
cules in the liquid. Their high water content allows vapor
and oxygen transmission to the wounds such as pressure
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and burns. They seem to play an important role as emer-
gency burns treatment alone or in combination with other
products, thanks to their cooling and hydrating effect [63].
For example, Burnshield hydrogel burn dressing (Levtrade
International) present even in ﬁrst aid kits is a polyure-
thane foam containing 96% of water and 1.06% Melaleuca
alternifolia extract [64].
Hydrogel dressings are also used for granulating cavity
wounds [65]. Amorphous gels are generally reapplied
every day while sheet hydrogels are usually changed 2–3
times a week [66] (see Table 3).
In 1992 Cartmell and Sturtevant [72] proposed a trans-
parent wound dressing as thin-ﬁlm, with a non-adhesive
central portion containing hydrogel material which
included polypropylene glycol or polyethylene glycol, and
isophorone diisocyanate. This product is described as being
ﬂexible in order to facilitate its removal, and transparent to
permit constant observation of the wound healing process.
Cartmell describes that the edges of this dressing adhere to
the skin due to the adhesive layers that protect the wound
site from bacteria and foreign bodies. Two years later in the
US Patent 5,423,737 Cartmell at al. [73] disclosed an
improved version of this transparent wound dressing. In
this case there was a release tab inserted between the
transparent layer and the release liner. The invention was
intended to respond to a need for a cost-effective product
which was simple to manufacture and easy to handle
and apply. A similar device has been presented by Holm
et al. [74], in which a hydrogel pad is included within an
adhesive dressing. This demonstrates that many attempts
have been made using new technologies but having the
same patient goals.
If local or systemic infection is compromising the
wound, or could compromise the healing process, one pos-
sible therapeutic approach would be to use dressings con-
taining antimicrobial agents, such as iodine or silver. Silver
is useful against a large range of microorganisms, including
Pseudomonas aeruginosa and Staphylococcus aureus [75].
These two opportunistic pathogens are frequently present
in chronic wounds and their mechanism of action includes
a bioﬁlm-based infection in the host [76]. A ‘critical coloni-
sation’ resulting from a multiplication of bacteria is nor-
mally accompanied by an increase in pain. Even if the
correct treatment is chosen, the healing process could be
delayed by a ‘critical colonisation’ which can result in theTable 3
Some examples of hydrogels and hydrogel sheets as wound dressings.
Product Main constituents Main
Granugel (ConvaTec) Pectin, carboxymethylcellulose
and propylene glycol
A cle
woun
heali
Intrasite Gel (Smith & Nephew) Modiﬁed carboxymethylcellulose
(2.3%) and propylene glycol (20%)
Amor
woun
Purilon Gel (Coloplast) Sodium carboxymethylcellulose
and more than 90% of water
Indic
woun
Aquaﬂo™ (Covidien) Polyethylene glycol and
propylene glycol
It has
caviti
Woundtab (First Water) Sulphonated copolymer,
carboxymethylcellulose, glycerol
and water
The d
and r
chronformation of a thick slough that is not responsive to stan-
dard debridement techniques and a malodour. Bacteria
levels should be reduced to a minimum to allow the wound
toheal, and the topical applicationof anantimicrobial dress-
ing is one of the most common ways to achieve this effect
[75]. US Patent 8,431,151 B2 proposed a method to manu-
facture a hydrogel antimicrobial non-woven ﬁbrous dress-
ing with controlled release of silver ions. The inventors
describe a PEG-based multi-block thermoplastic polyure-
thane incorporating polyhedral oligomeric silsesquioxane,
forming organic–inorganic hybrid hydrogels with unique
mechanical properties and adjustable swelling ratios. In this
case a nanoﬁber network, produced with the electro-spin-
ning technique, was used to deliver silver ions. AgNO3 was
directly incorporated into polymer/dimethylformamide
solutions to prepare the antimicrobial scaffolds [77].
Hydrogels have been included in the structure of some
wound dressings together with other materials, forming
composite products suitable for many types of wounds.
Shah et al. [78] described a material composed of a cotton
gauze, or other ﬁbrous substrate, impregnated with a ther-
moplastic hydrogel forming polymer. The polymers
included A–B–A block copolymers, multiblock copolymers,
graft copolymers and polymer blends each incorporating a
hydrophilic (such as polyethylene oxide or poly(hydroxyal-
kyl methacrylate)) and a hydrophobic component (such as
polystyrene, poly(methyl methacrylate) or polyesters).
The hydrogel showed microphase separation of the hydro-
phobic portion becoming water-insoluble but remaining
water-swellable. By absorbing thewoundexudate, the com-
posite dressing could assume a slimy consistency avoiding
the adherence to thewound surface that could cause further
trauma, and allowing more infrequent changes.
Future developments in wound care products will
depend on continued demands from public and healthcare
professionals [79]. The important challenge for the future
is to establish the appropriate wound care strategy for
every single patient, and this can be achieved only by offer-
ing the optimal products. Innovative dressings need to be
developed while their production costs must be kept low.4. Drug delivery
Many patents and academic papers about possible
applications of hydrogels in drug delivery have beencharacteristics
ar, viscous hydrogel for the management of partial and full-thickness
ds, may be used as a ﬁller for dry cavity wounds to provide a moist
ng environment [67]
phous sterile hydrogel dressing for use in shallow and deep open
ds [68]
ated in conjunction with a secondary dressing for necrotic and sloughy
ds and ﬁrst and second degree burns [69]
a disc shape that maximizes wound coverage and helps to ﬁll shallow
es. Translucent gel that allows wound visualization [70]
ressing contains a superabsorbent polymeric gel able to absorb bacteria
etain them in its structure. Described as a wound ‘kick-starter’ patch for
ic wounds, it can also be used as a secondary absorbent [71]
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cial products. Hydrogels have attracted noticeable interest
for their use in drug delivery due to their unique physical
properties [80–82]. The high porosity that characterizes
hydrogels can easily be adjusted by controlling the density
of cross-links in their matrix and the afﬁnity to water.
Their porous structure also allows drugs to be loaded and
then released. The advantages offered by hydrogels for
drug delivery applications include the possibility for sus-
tained release, which results in maintaining a high local
concentration of an active pharmaceutical ingredient over
a long period [80]. The drug can be loaded into a hydrogel
and then its release may proceed through several mecha-
nisms: diffusion controlled, swelling controlled, chemically
controlled and environmentally-responsive release.
The diffusion controlled release systems can be repre-
sented by reservoir or matrix devices. Both allow the drug
release by diffusion through the hydrogel mesh or the
pores ﬁlled with water. A reservoir delivery system
(Fig. 8) includes a drug-containing core coated with a
hydrogel membrane, commonly available as capsules, cyl-
inders, spheres or slabs. The concentration of the drug is
higher in the centre of the system to allow a constant
release rate [83].
In matrix systems the drug is dispersed or dissolved
uniformly throughout the three-dimensional structure of
the hydrogel (Fig. 9). Drug release is achieved through
the macromolecular mesh or the pores, and the initial
release rate in this case is proportional to the square root
of time, rather than being constant and time independent
as happens in reservoir systems [83].
In swelling-controlled release devices the drug is dis-
persed within a glassy polymer as in a matrix device, and
when the polymer is in contact with a bio-ﬂuid it starts
swelling. The material then expands beyond its boundary
allowing the diffusion of drug with the relaxation of poly-
mer chains [83]. This process is also called Case II transport
and it shows constant, time-independent kinetics of
release. It is known as ‘anomalous transport’, one that
combines swelling-controlled release with diffusion [84].
The gradient existing between the dispersed drug in the
hydrogel and the surrounding environment permits the
diffusion of the active ingredient loaded from the high con-
centration through the hydrogel, to the lower one [85]. TheFig. 8. Scheme of drug release through a hydmolar ﬂux of the drug in this case, J (mol/cm2s), is propor-
tional to the concentration gradient (Dc) as the driving
force for this process:
J ¼ D  Dc; ð5Þ
where D is the diffusion coefﬁcient in the polymer (cm2/s),
and c is the concentration of the drug within the polymer
(mol/cm3). The release rate normally depends on the time
so the release kinetics is determined from:
@c=@t ¼ D  J ¼ D  ðD  DcÞ ð6Þ
This equation describes the transport of drug out of the
hydrogel when the boundary is static (static drug delivery)
[86].
The hydrogel-based dosage forms can have different
designs and shapes depending on the route of drug admin-
istration (Table 4).
The topical application of hydrogels can effectively be
used to deliver drugs that can help to alleviate the symp-
toms of many pathological conditions. For instance, Nho
et al. [101] proposed a therapeutic hydrogel made of poly(-
vinyl alcohol) or poly(vinylpyrrolidone) for the treatment
of atopic dermatitis. This product contained an extract
from medicinal plants such as Houttuynia cordata, elm, cel-
andine and Canavalia gladiata, which could be used for the
treatment of dermatitis. To prepare this hydrogel
poly(vinylpyrrolidone) and poly(vinyl alcohol) were dis-
solved in the medicinal plant extract. Then, the solution
was left to set to produce a gel. It is possible to freeze/thaw
the cast and introduce physical cross-links into the gel.
Finally the physical gel must be treated with gamma, UV-
or electron beam-radiation to initiate chemical cross-link-
ing and to sterilize the ﬁnal product. The hydrogel was
supported by a hydrophilic non-woven fabric sheet and
an air-permeable polyethylene ﬁlm.
Furthermore, hydrogels are suitable for transdermal
iontophoretic delivery of drugs, as was demonstrated in
the European Patent Application EP 0 524 718 A1, where
polyurethane hydrogel matrices were used as monolithic
drug reservoirs. These hydrogels were synthesized from
mixtures prepared by adding a prepolymer solution con-
taining an isocyanate-capped oxyalkylene-based prepoly-
mer in anhydrous aprotic organic solvent to water. When
the organic solvent has evaporated completely, theDrug diﬀusion from the 
core through the hydrogel 
membrane 
rogel membrane in a reservoir system.
Fig. 9. Drug release from matrix systems.
Table 4
Main types of hydrogel-based products applied via different routes of drug administration.
Route of
administration
Shape Typical dimensions References
Peroral Spherical beads 1 lm to 1 mm [87,88]
Discs Diameter of 0.8 cm and thickness of 1 mm [89]
Nanoparticles 10–1000 nm [90]
Rectal Suppositories Conventional adult suppositories dimensions (length 32 mm) with a central cavity of 7 mm
and wall thickness of 1.5 mm
[91]
Vaginal Vaginal tablets Height of 2.3 cm, width of 1.3 cm and thickness of 0.9 cm [92]
Torpedo-shaped
pessaries
Length of 30 mm and thickness of 10 mm [93]
Ocular Contact lenses Conventional dimensions (typical diameter 12 mm) [94]
Drops Hydrogel particles present in the eye drops must be smaller than 10 lm [95]
Suspensions
Ointments
N/A [96]
Circular inserts Diameter of 2 mm and total weight of 1 mg (round shaped) [97]
Transdermal Dressings Variable [1]
Implants Discs Diameter of 14 mm and thickness of 0.8 mm [98]
Cylinders Diameter of 3 mm and length of 3.5 cm [99,100]
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iontophoresis is deﬁned as the transport of ionic drugs
through the skin, driven by a very weak electric current.
The applied current helps to transfer the ionized drugs
through the stratum corneum into the dermis, in which
the active ingredient can diffuse into capillaries and then
into the systemic circulation. Alternatively, hydrogel com-
positions can be employed as passive transdermal reser-
voirs. The hydrogels used in the aforementioned work
showed a high swelling ratio, good ﬂexibility, strength
and transparency [102].
Hydrogels could be useful as ocular drug delivery carri-
ers, not only in the form of lenses as previously discussed.
The US Patent 8,409,606 B2 presented a system that pro-
vided the release of speciﬁc drugs through punctal plugs.
In this work very soft biodegradable covalently cross-
linked hydrogels with high-swelling capability were used,
in order to be able to remain in situ (in the punctum or lac-
rimal canal) with greater comfort for the patient. The sys-
tem could be designed to be ‘temporary’ or ‘permanent’
and the plugs could be accordingly made of collagen or sil-
icone, respectively [103].
Ocular therapeutics™ produces ophtalmic drug delivery
systems and medical devices using poly(ethylene glycol)
hydrogels. For instance, dexamethasone punctum plug isdesigned for the controlled release of the corticosteroid
in case of post-operative inﬂammation and pain and it
has entered the Phase 3 trials. After a four-week treatment
period, during which the plug releases the drug from the
canaliculus to the ocular surface, it is naturally removed
via the nasolacrimal system [104].
Ideally a drug delivery system should be synchronized
with the physiological status of the patient and should pro-
vide drug release in response to changes in environment.
Moreover, if the drug exhibits some side effects, its release
when it is not required can cause additional problems.
Hydrogels can show changes in their swelling behavior,
structure, permeability or mechanical properties in
response to various internal and external stimuli [87].
Bae et al. [105] proposed a delivery device capable of
releasing a drug enclosed within a hydrogel, which des-
wells responding to a chemical or physical stimulation
(change in temperature, pH, ionic strength or glucose con-
centration). It utilises either temperature- or pH- sensitive
hydrogels already used in drug delivery as cross-linked
homopolymers or copolymers, such as the N-isopropylac-
rylamide based copolymers or cross-linked weak polyelec-
trolytes. The system presented by Bae et al. [105] was
composed of a ‘sponge-like’ porous gel conﬁned in a walled
structure permeable to the loaded drug. Thus, it was
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could be pulsatile if needed.
Biodegradable and nontoxic multi-block hydrogel
copolymers have been used as drug delivery matrices
and described in the US Patent 5,514,380. They were syn-
thesized from a hydrophilic soft block and a hydrophobic,
biodegradable hard block. Their degradation could be
achieved with the hydrolysis of intramolecular ester and
amide bond that easily occurred in the human body.
Polyethyleneoxide (PEO) and/or copolymers of PEO/
polypropyleneoxide (PPO) with molecular weight of 600–
30,000 Da met the required qualities of the hydrophilic,
non-biodegradable polymers employed in the mentioned
patent. The biodegradable block could instead be repre-
sented by polylactide (PLA), polyglycolide (PGA) or a PLA/
PGA copolymer [106].
US Patent 8,383,153 B2 describes a poly(amidoamine)
based hydrogel for application as drug carriers. This tem-
perature- and pH-sensitive hydrogel had a molecular
structure developed to avoid the initial burst drug release
and was instead capable of providing a sustained release.
The material can be produced by a one-step process by
coupling between secondary amine groups (ANH) of a dia-
mine compound (such as piperazine) and vinyl groups
(CH2@CHA) of an alkylene bisacrylamide compound (e.g.
N,N0-methylenebisacrylamide (MDA) or N,N0-ethylenebis-
acrylamide). This hydrogel can be used as a carrier for dif-
ferent types of physiologically active compounds, using
different routes of administration [107].
A drug delivery system comprising a hydrogel and a
catheter were also proposed in US Patent 7,066,904 B2.
The catheter allows the incorporation and the immobilisa-
tion of a relevant amount of drug into the hydrogel, and
then its release by a triggering agent or different condition
in the desired location. In this case the polymers used, such
as (hydroxyethyl)methacrylate-co-methacrylic acid, are
pH-sensitive in order to produce hydrogels able to undergo
a volume phase transition at a speciﬁc pH. A salt solution,
such as sodium phosphate or sodium bicarbonate can be
used to alter the microenvironment within the device
and trigger the release of the active ingredient. In fact,
the pH of this solution could be in the range of 7.5–8.4 or
in the range of 6.4–7.3, and could cause alternatively
swelling or contraction of the hydrogel [108].
One of the successful examples of hydrogels for drug
delivery is the vaginal insert Cervidil for cervical ripening,
which has been on the market since 1995. This controlled
release formulation has been used to induce or bring on
labor in patients who are at or near the time of delivery.
Each insert contains 10 mg of dinoprostone (prostaglandin
E2 or PGE2) in 271 mg of cross-linked polyethylene oxide/
urethane polymer and it releases the drug over a period
of 12 h at approximately 0.3 mg/h. The drug release is trig-
gered by the hydrogel swelling when placed in a moist
vaginal environment [109].
Controlled Therapeutics Scotland Ltd. has developed a
misoprostol vaginal insert (MVI) that uses the same deliv-
ery system as the Cervidil, but contains misoprostol, a
cytoprotective agent active on the cervix and uterus to
induce labor. The same company is currently developing
a modiﬁed release hydrogel buccal patch (Pilobuc™) con-taining pilocarpine, for the treatment of symptoms of Sjö-
gren’s syndrome, a systemic autoimmune disease in which
exocrine glands that produce tears and saliva are destroyed
by the immune cells [110].
A hydrogel subcutaneous insert in the form of reservoir
system, called SUPPRELIN LA (Endo Pharmaceuticals Solu-
tions Inc.), for the release of histrelin acetate is available on
the market. Histrelin acetate is a gonadotropin-releasing
hormone (GnRH) agonist indicated for the treatment of
children with central precocious puberty (CPP). It produces
a decrease in luteinizing hormone (LH) levels and sex ste-
roids serum concentration within the ﬁrst month of treat-
ment. The implant is made of a hydrogel prepared from 2-
hydroxyethyl methacrylate, 2-hydroxypropyl methacry-
late, trimethylolpropane trimethacrylate, benzoin methyl
ether, Perkadox-16, Triton X-100 and contains 50 mg of
histrelin, which is delivered over 12 months time (approx-
imately 65 mcg per day). After this period the device needs
to be removed as it is nonbiodegradable [111].
Park et al. [112–115] had proposed the use of superpor-
ous hydrogel compositions as gastric retentive devices for
long-term oral drug delivery. These hydrogels were pro-
duced starting from (meth)acrylic acid or (meth)acrylam-
ide, a so-called ‘disintegrant’, represented by a natural or
synthetic cross-linked hydrophilic polymer such as cross-
linked carboxymethylcellulose or poly(vinyl pyrrolidone)
and a cross-linking agent such as N,N0-methylenebisacryla-
mide. They were synthesized using the gas blowing tech-
nique where polymerization and foaming (with sodium
carbonate or bicarbonate as foaming agent) take place at
the same time. More speciﬁcally, in this process the poly-
merization has to start only a few minutes after the begin-
ning of foaming in order to entrap the gas bubbles in the
network. The ﬁnal device was able to remain in the stom-
ach up to more than 24 h allowing the slow release of the
drug loaded.
Hydrogel devices were suggested for oral delivery of
different active ingredients, e.g. non-steroidal anti-inﬂam-
matory drugs (NSAIDs) [116]. They can be used to protect
drugs or proteins (e.g. insulin) susceptible to the proteo-
lytic degradation that occurs in the stomach [117,118]. In
the US Patent application WO1998043615 A1 [119] a
hydrogel matrix made of poly(methacrylic acid-g-ethylene
glycol) cross-linked with tetraethylene glycol dimethacry-
late is presented. This hydrogel could be loaded with insu-
lin simply by immersing it into its solution at pH 7.4. When
administered orally, insulin will be protected from the
acidic environment of the stomach by the formation of
inter-chain complexes within the hydrogel network.
Hydrogen bonding between the carboxyl and the ether
groups on the grafted chains stabilized these complexes
at acidic pH. These hydrogels exhibited pH-sensitive swell-
ing behavior: once in the upper small intestine (at higher
pH), the complexes dissociate increasing the pore size
and allowing the insulin to be released from the matrix.
Additionally, the ability of these hydrogels to strongly
adhere to the intestinal mucosa signiﬁcantly improves
the release and absorption of the protein [117,119].
In the future, hydrogel-based products could represent
a signiﬁcant proportion of drug delivery systems, to suc-
cessfully administer drugs at the desired rate and site in
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could be achieved with the development of new hydrogels
with different hydrophobicity/hydrophilicity and struc-
tural characteristics. These systems could improve the
delivery of more sensitive molecules and be employed in
the treatment of pathologic conditions such as diabetes
or even cancer. Speciﬁcally, more developments are
expected in the use of hydrogels for delivery of therapeutic
proteins and peptides.
5. Tissue engineering
There are millions of patients suffering from the loss or
failure of an organ or a tissue caused by an accident or a
disease every year. Over 8 million surgeries are conducted
to treat these patients in the U.S. each year, and the overall
cost of these issues to the U.S. economy is estimated to be
around $400 billion per year. Tissue and organ transplanta-
tions represent generally accepted therapies, but they are
drammatically limited by donor shortages [120].
The term ‘‘tissue engineering’’ was originally deﬁned in
1988 as the ‘‘application of the principles and methods of
engineering and life sciences toward fundamental under-
standing of structure–function relationship in normal and
pathological mammalian tissues and the development
of biological substitutes for the repair or regeneration
of tissue or organ function’’ [121]. In other words, it
involves the improvement or replacement of speciﬁc
tissues or organs using engineered materials and synthetic
strategies.
Tissue engineering is a more recent application of
hydrogels, in which they can be applied as space ﬁlling
agents, as delivery vehicles for bioactive substances or as
three-dimensional structures that organize cells and pres-
ent stimuli to ensure the development of a required tissue
(Fig. 10). Space ﬁlling agents are the most commonly used
group of scaffolds and they are employed for bulking, to
prevent adhesion, and as a biological ‘glue’. Drugs can beFig. 10. Hydrogels in tissue engineering (reprinted from E.S. Place, J.H. George, C.K
permission from the Royal Society of Chemistry).delivered from hydrogel scaffolds in numerous applica-
tions including promotion of angiogenesis and encapsula-
tion of secretory cells. Additionally, hydrogel scaffolds
have also been applied to transplant cells and to engineer
many tissues in the body, including cartilage, bone, and
smooth muscle [122].
An indispensable property is the biocompatibility of
hydrogels, which could be deﬁned as the ability of a mate-
rial to be in contact with the body organs without any
damages for the surrounding tissues and without trigger-
ing any undesirable response [114]. Synthetic materials
capable of forming hydrogels suitable for tissue engineer-
ing include poly(ethylene oxide), poly(vinyl alcohol),
poly(acrylic acid), poly(propylene fumarate-co-ethylene
glycol), and polypeptides. Agarose, alginate, chitosan, col-
lagen, ﬁbrin, gelatin, and hyaluronic acid are naturally
derived polymers that could also be used for this purpose
[124,125].
In European patent EP 1 664 168 B1, an interesting
hydrogel-based composition for manufacturing porous
scaffolds has been presented. It was composed of a biode-
gradable unsatured self-cross-linkable polymer such as
poly(propylene fumarate), biodegradable hydrogel micro-
particles (diameters of 1–1000 lm) entrapping water and
a free-radical initiator promoting the cross-linking process.
The microparticles were made of cross-linked collagen or
gelatin and can contain a biologically active substance.
The method disclosed ‘super-absorbent semi-solid’ hydro-
gel microparticles, able to swell in water but not to ﬂow as
a liquid, with a deﬁned shape due to the cross-linking.
After the polymerization process, the scaffold formed with
the mixture could be used directly for the treatment of
skeletal defects without leaching out the hydrogel porogen
[125].
Harris et al. [126] described a tissue engineering scaf-
fold with the beneﬁts of microporous and nanoporous scaf-
folds, comprising a nanoﬁbrous and nanoporous hydrogel
formed from self-assembling peptides, which are. Williams, M.M. Stevens, Chem. Soc. Rev. 2009, 38, 1139–1151 [123] with
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with cells. They were able to stimulate tissue ingrowth
and vascularization, and furthermore, this hydrogel could
be used for slow-diffusion drug delivery. The self-assem-
bling peptides used to form hydrogels should have alter-
nating hydrophobic and hydrophilic amino acids (more
than 8). For instance, one of them had the following amino
acid sequence: Arg–Ala–Asp–Ala–Arg–Ala–Asp–Ala–Arg–
Ala–Asp–Ala–Arg–Ala–Asp–Ala. This peptide is commer-
cialized as ‘PURAMATRIX’ (3-D Matrix, Inc., Cambridge,
Mass.) Its self-assembly could easily take place in tissue
culture medium (Dulbecco Modiﬁed Eagle’s Medium, Gib-
co BRL, Gaithersburg, Md) containing calf serum. The scaf-
folds presented might also be applied to open wounds or
be surgically implanted. It was established that scaffolds
made of only one component or phase may not produce
the ideal environment for supporting tissue regeneration.
Conversely, the so-called ‘hybrid’ materials were found to
give better results, in terms of cell proliferation, differenti-
ation and migration.
Hydrogels scaffolds are used for cell-sheet and tissue
production. Kumar [127] has recently disclosed a method
to produce biodegradable poly(vinyl alcohol) hydrogels
complexed with phenylboronate-containing polymers able
to encourage cell and tissue growth. PCCs include a phe-
nylboronate ligand (such as 4-vinylphenylboronic acid),
an acrylic monomer (such as N-isopropylacrylamide or
acrylic acid) and an alkaline tertiary amine (such as N,N-
dimethylaminoethylmethacrylate). The cells which could
be represented for example by keratinocytes or ﬁbroblasts,
are cultured for 5–20 days on the hydrogel scaffolds. It is
then possible to collect the cell layers formed by simply
dissolving the hydrogel scaffolds using a saccharide solu-
tion (such as fructose or mannitol solution). This saccha-
ride biodegradation is possible due to the presence of
phenylboronate ligands that are derivatized forms of phen-
ylboronic acid, which can establish reversible covalent
interactions with 1,2 or 1,3-cis-diol-containing compounds
such as carbohydrates.
Blanchard et al. [128] has reported the use of pure
cross-linked keratin-based hydrogels for tissue engineer-
ing cell scaffolds. Keratin is biocompatible, and non-
immunogenic biopolymer that promotes epithelialization
process and can be extracted from patient hair or nails.
After puriﬁcation and partial oxidization of the keratin,
the sulfonic acid residues of the protein, which are
hydrophilic, form disulﬁde cross-links between back-
bones and bind water. Additional hydrogen bonds are
then formed in this hydrogel. The material was shown
to be suitable as nutrient support and scaffold for cell
growth.
Song et al. [129] has proposed beta-glucan-based
hydrogel scaffolds for tissue engineering produced by radi-
ation fusion technology. Beta-glucan (beta-1,6-branched-
beta-l,3-glucan) can promote cell regeneration and
collagen biosynthesis, and it is recognized to be safe and
biocompatible. It could be extracted from different fungi
such as Schizophyllum commune or Ganoderma lucidum
and dissolved in distilled water. This aqueous solution
was then cast in petri dishes and irradiated for the cross-
linking step using electron, gamma or UV beam at a doseof 5–50 kGy to form a gel. Stem cells could rapidly adhere,
grow and differentiate on the scaffold formed.
One of the most important future challenges in tissue
engineering is how polymers could be used to stimulate
the blood vessel network formation in the desired tissue,
essential to supply its needs. Hydrogels could represent a
valid option to effectively control the vascularization pro-
cess, by local delivery of both angiogenic factor and endo-
thelial cells to the intended area [120]. Additionally, many
types of tissue such as bone, muscle or blood vessels are
located in areas requiring excellent mechanical properties
that the majority of the currently available hydrogels do
not show, so new approaches should be investigated in
the future to achieve better results.6. Hygiene products
Superabsorbent polymers (SAPs) have been introduced
into the agriculture and diaper industry about thirty years
ago, and since then their uses have been extended to sev-
eral other applications due to their excellent water reten-
tion [130]. SAPs have been ﬁrstly commercially produced
in Japan in 1978 for use in feminine napkins, and this early
material was represented by a cross-linked starch-g-
polyacrylate [131].
At the end of the 90s, ‘superporous hydrogels’ (SPHs)
were introduced and presented as a different type of
water-absorbent polymer system. As SAPs, SPHs are
formed by covalently cross-linked hydrophilic polymers,
but unlike SAPs, they show an exceptional size-indepen-
dent fast swelling kinetics. The ﬁrst generation of SPHs
was generally made from highly hydrophilic acrylamide,
salts of acrylic acid and sulfopropyl acrylate. Later genera-
tion of SPHs are represented by ‘hydrid SPHs’ produced by
adding a so-called ‘hybrid agent’ (natural or synthetic
water-soluble or dispersible polymer capable of chemical
or physical cross-linking) to the SPH previously made.
With this method it is possible to generate an interpene-
trating polymeric network. For example, acrylamide-based
SPH is synthesized in the presence of sodium alginate and
after that, a cross-linking occurs between alginate chains
and calcium ions forming a ‘hybrid SPH’. These more recent
SPHs have shown better and more useful qualities, such as
high mechanical strength and elasticity even in swollen
state [130]. Superabsorbent hydrogels, in particular the
acrylate-based materials, are extensively used in hygiene
products to absorb ﬂuids. In fact they are able to hold
moisture away from the skin, promoting skin health, pre-
venting diaper rash and providing a comfortable use. Par-
ents in all the industrialized countries as well as
hospitals around the world employ disposable diapers con-
taining SAPs [132].
A further increase in the use of these materials is
observed in training pants and adult incontinence product
markets. SAPs can also prevent the colonization of germs,
reducing the risk of fecal contaminations and potential
spread of gastrointestinal infections. The ﬁrst use of SAPs
in the diaper industry was proposed in 1982 by Unicharm
in Japan, with its subsequent use in sanitary napkins. After
that, diapers became thinner and also had improved water
E. Caló, V.V. Khutoryanskiy / European Polymer Journal 65 (2015) 252–267 265retention performance. It was possible to develop diapers
with leakage values below 2% and the standard weight of
a medium size diaper could be reduced by about 50%, with
some obvious advantages in terms of environmental issues
and reduced manufacturing costs [132].
Regarding the ecological impact of disposable diapers
and similar products, it is relevant to consider current dia-
per consumption. For instance, a child within the 30th
month uses approximately six diapers a day and each of
them has a volume of 500 cm3, so only one child produces
on average 3000 cm3 of litter a day, i.e. 1092 cubic meters
every year [132]. Making recyclable disposable diapers,
napkins, hospital bed sheets, sanitary towels and other
similar products is therefore one of the vital targets for
the modern industry. An innovative solution to this prob-
lem has recently been proposed, which involves the use
of cellulose-based hydrogels, which are totally biodegrad-
able. Novel types of hydrogels, containing sodium carboxy-
methylcellulose (NaCMC) and hydroxyethyl cellulose
(HEC) cross-linked with divinyl sulfone (DVS), can swell
like SAPs, and exhibit high water retention under centrifu-
gal loads. These improvements were achieved by introduc-
ing microporous structures into the hydrogel, which
increases water retention and swelling kinetics due to cap-
illarity effects [132].
US Patent 32,649 describes one of the ﬁrst hydrogel-
forming polymer compositions suitable for hygiene prod-
ucts manufacturing. It consisted of a water-insoluble,
slightly cross-linked polymeric material, which could be
prepared from carboxylic acids and acid anhydrides, or
oleﬁnically unsatured sulfonic acids, using a free-radical
polymerization in the presence of a cross-linking agent in
an aqueous solution. This material could be dried to result
in polymer compositions capable to form hydrogels upon
contact with water or bodily ﬂuids [133]. Only a few years
later, in US Patent 5,009,653, Osborn proposed a product
consisting of a thin and ﬂexible sanitary feminine napkin
with an absorbent core placed between two air-laid tissue
sheets. The core was composed of a hydrogel-forming
material, prepared from acidic monomers such as acrylic
acid, methacrylic acid or 2-acrylamido-2-methyl propane
sulfonic acid. This material was highly absorbent, could
withstand medium to high menstrual ﬂows and was very
conformable to the body of a user, preventing the risk of
leakage and staining [134].
Many attempts have been made to develop new prod-
ucts, which could not only swell, but also retain the ﬂuids
absorbed under external pressure or against an applied
restraining force. An absorbent material composed of a
porous matrix of ﬁbers and superabsorbent hydrogel is
described in the US Patent 5,147,343, which has the capa-
bility to initially imbibe ﬂuids and swell, while being
exposed to a load. The matrix can be formed from wood
pulp or cotton linters as well as synthetic ﬁbers (polyethyl-
ene, polypropylene polyesters etc.) and the hydrogel could
be produced from polyacrylamides, polyvinyl alcohol, eth-
ylene-maleic anhydride copolymers or polyvinyl ethers.
The ‘Absorbency Under Load’ (AUL) is deﬁned as the vol-
ume of 0.9 wt% NaCl solution which the superabsorbent
composition could absorb per 1 g in one hour, being sub-
jected to a load of 21,000 dynes/cm2. Hence, the work(W) performed by the material could be calculated using
the following formula [135]:
W ¼ ðAULÞ  ðRestraining forceÞ ð7Þ
Pampers (owned by Procter & Gamble) and Huggies
(from Kimberly–Clark) are the two most widely used dis-
posable diaper brands, with about 35% and 22% global mar-
ket share, respectively. Both are sold in over 50 countries
and they have wide range of products. Manufacturers have
been focusing their efforts on enhancing the production
and engineering of SAPs with better properties, i.e. higher
AUL, lower levels of residual monomers (RM) and soluble
fractions [136]. Further developments in this area are
expected with the formulation of the materials containing
enzymes and other additives to prevent infections and
unpleasant smells. Additionally, taking the scale of produc-
tion of these materials into consideration, there is a clear
need in environmentally friendly hygiene products that
undergo biodegradation.
7. Conclusions
Hydrogels are widely present in everyday products
though their potential has not been fully explored yet.
Thesematerials already have awell-established role in con-
tact lenses, hygiene products and wound dressing
markets but commercial hydrogel products in tissue
engineering and drug delivery are still limited. Many
hydrogel-based drug delivery devices and scaffolds have
been designed, studied and in some cases even patented,
however not many have reached themarket. More progress
is expected in these two areas. Limited commercial prod-
ucts with hydrogels in drug delivery and tissue engineering
are related to some extent to their high production costs.
Acknowledgements
The analysis of literature presented in this review was
partially supported by BBSRC (BB/FOF/PF/11/08 and BB/
FOF/289). EC acknowledges the University of Reading for
funding her doctoral studies. Thanks to Brett Symonds,
Samuel Bizley and Peter Morrison for their help and sup-
port during the preparation of this review.
References
[1] Peppas NA, Bures P, Leobandung W, Ichikawa H. Eur J Pharm
Biopharm 2000;50:27–46.
[2] Hoffman AS. Adv Drug Deliv Rev 2012;64:18–23.
[3] Rosiak JM, Yoshii F. Nucl Instrum Meth B 1999;151:56–64.
[4] Khutoryanskiy VV, Khutoryanskaya OV, Cook JP, Goodall GW. US
Patent application 2013/0018110 A1; 2013.
[5] Montoro SR, de Fátima Medeiros S, Alves GM. Chapter 10 –
nanostructured hydrogels. In: Nanostructured polymer
blends. Oxford: William Andrew, Elsevier; 2014. p. 325–55.
[6] Mathur AM, Moorjani SK, Scranton AB. J Macromol Sci Polym Rev
1996;36:405–30.
[7] Ahmed EM, J Adv Res, open access <http://dx.doi.org/10.1016/
j.jare.2013.07.006>; 2013 [accessed June 2014].
[8] Park KR, Nho YC. J Rad Phys Chem 2003;67:361–5.
[9] Rosiak JM, Ulan´ski P, Pajewski LA, Yoshii F, Makuuchi K. Radiat Phys
Chem 1995;46:161–8.
[10] Lin-Gibson S, Bencherif S, Cooper JA, Wetzel SJ, Antonucci JM, Vogel
BM, et al. Biomacromolecules 2004;5:1280–7.
[11] Rosiak J, Ruciska-Rybus A, Pekala W. US Patent 4,871,490; 1989.
266 E. Caló, V.V. Khutoryanskiy / European Polymer Journal 65 (2015) 252–267[12] Kikgel website. <www.kikgel.com> [accessed January 2013].
[13] Cook JP, Goodall GW, Khutoryanskaya OV, Khutoryanskiy VV.
Macromol Rapid Commun 2012;33:332–6.
[14] Majmudar A. US Patent 8,268,345 B2; 2012.
[15] Pal K, Banthia AK, Majumdar DK. Des Monomers Polym
2009;12:197–220.
[16] Klouda L, Mikos AG. Eur J Pharm Biopharm 2008;68:34–45.
[17] Peppas NA. Hydrogels in medicine and pharmacy: properties and
applications, vol. 3. CRC Press Inc.; 1987. p. 1–208.
[18] Barbucci R. Hydrogels: biological properties and
applications. Milan: Springer-Verlag Italia; 2009. p. 1–179.
[19] Stein DB. Handbook of hydrogels – properties, preparation &
applications. New York: Nova Science Publishers, Inc.; 2009.
[20] Kamath KR, Park K. Adv Drug Deliv Rev 1993;11:59–84.
[21] Rimmer S. Biomedical hydrogels– biochemistry, manufacture and
medical applications. Woodhead Publishing; 2011.
[22] Bouten PJM, Zonjee M, Bender J, Yauw STK, van Goor H, van Hest
JCM, et al. Prog Polym Sci 2014;39:1375–405.
[23] Wichterle O, Lim D. Nature 1960;185:117–8.
[24] Maldonado-Codina C, Efron N. Optometry Practice 2003;4:101–15.
[25] Loyd AW, Faragher RGA, Denyer SP. Biomaterials 2002;22:
769–85.
[26] Hamilton RS, Mcfarlane SD. Patent application WO2005011966 A1;
2006.
[27] Turner DC, Steffen RB, Wildsmith C, Matiacio TA. US patent
6,861,123 B2; 2005.
[28] Port MJA. Optometry Today 1999;30:27–36.
[29] Osuagwu UL, Ogbuehi KC. Contact Lens Anterior Eye
2014;37:136–43.
[30] Patel S, Marshall J, Fitzke 3rd FW. J Refract Surg 1995;11:100–5.
[31] Patel S, Alió JL, Pérez-Santonja JJ. Invest Ophth Vis Sci
2004;45:3523–30.
[32] Hadassah J, Sehgal PK. Clin Exp Optom 2006;89:374–80.
[33] Efron N, Morgan PB, Cameron ID, Brennan NA, Goodwin M.
Optometry Vision Sci 2007;84:328–37.
[34] Harvitt DM, Bonanno JA. Optometry Vision Sci 1999;76:712–9.
[35] Morrison DR, Edelhauser HF. Invest Ophth Visual 1972;11:58–63.
[36] Ketelson HA, Meadows DL, Stone RP. Colloid Surf B 2005;40:1–9.
[37] Francis CA, Zheng Y, Xu Y, Yao L, Back A, Hong Y, et al. US Patent
0220743A1; 2012.
[38] Robitaille M, Shi J, McBride S, Wan KT. J Mech Behav Biomed
2013;22:59–64.
[39] Jacob JT. Eye Contact Lens 2013;39:13–9.
[40] Wichterle O. US Patent 3,679,504; 1972.
[41] Chromecek R, Bohdanecky M, Kliment K, Otoupalova J, Stoy V, Stol
M, et al. US Patent 3,575,946; 1971.
[42] Neefe CW. US Patent 4,472,327; 1984.
[43] Kunzler JF, Friends GD. US Patent 5,006,622; 1991.
[44] Lai Y, Quinn ET. US Patent 5,969,076; 1999.
[45] Nichols JJ. Contact Lens Spectrum 2013;28:24–9.
[46] Pinsley JB, Adams JP, Khanolkar A, Zanini D, Fadli Z, Clark MR, et al.
EP 2 365 360 A2; 2011.
[47] Gaylord NG. US Patent 3,808,178; 1974.
[48] French K. Optician 2005;230:20–8.
[49] Steffen R, Schnider C. Optician 2004;5954:23–5.
[50] Bauman ER, Hagmann P, Dallas Pruit J, Rappon M. US Patent
0314185 A1; 2012.
[51] Vista Optics website. <www.vistaoptics.com> [accessed July 2013].
[52] Hu X, Lingyun H, Wang H, Yang X, Zhang G, Wang G, et al. Int J
Polym Sci 2011;2011:1–9.
[53] Venkatesh S, Sizemore SP, Byrne ME. Biomaterials 2007;28:717–24.
[54] Xu J, Li X, Sun F. Acta Biomater 2010;6:486–93.
[55] Eccleston GM. The design and manufacture of medicines. 3rd
ed. Aulton’s Pharmaceutics, Churchill Livingston Elsevier; 2007. p.
598–605.
[56] Medaghiele M, Demitri C, Sannino A, Ambrosio L. Burn Trauma
2014:153–61.
[57] Turner TD. Pharm J 1979;222:421–4.
[58] Jones V, Grey JE, Harding KG. BMJ 2006;332:777–80.
[59] Beldon P. Wound Essentials 2010;5:140–4.
[60] Murphy PS, Evans GRD. Plast Surg Int 2012;2012:1–8.
[61] Agren MS. Acta Derm Venereol Suppl (stockh) 1990;154:1–36.
[62] Stashak TS. Clin Tech Equine Pract 2004;3:148–63.
[63] Osti E, Osti F. Ann Burns Fire Disasters 2004;3:137–41.
[64] Burnshield Emergency Burncare website. <www.burnshield.com>
[accessed November 2014].
[65] Jones A, Vaughan D. J Orthop Nurs 2005;9:1.
[66] Weir D. Wounds Int 2012;3:18–22.
[67] ConvaTec website. <www.convatec.co.uk> [accessed July 2013].[68] Smith & Nephew website. <www.smith-nephew.com> [accessed
July 2013].
[69] Coloplast website. <www.coloplast.co.uk> [accessed July 2013].
[70] Covidien website. <www.covidien.com> [accessed July 2013].
[71] First Water website. <www.ﬁrst-water.com> [accessed July 2014].
[72] Cartmell JV, Sturtevant WR. US Patent 5,106,629; 1992.
[73] Cartmell JV, Sturtevant WR, Bausmith WE, Wolf ML. US Patent
5,423,737; 1995.
[74] Holm DR, Burton SA, Asmus RA, Jacobson RL. US Patent 2011/
0166492 A1; 2011.
[75] Flores A, Kingsley A. Wound Essentials 2007;2:182–5.
[76] Fazli M, Bjarnsholt T, Kirketerp-Møller K, Jørgensen B, Andersen AS,
Krogfelt KA, et al. J Clin Microbiol 2009;47:4084–9.
[77] Mather P, Wu J, Ren D, Hou S. US Patent 8,431,151 B2; 2013.
[78] Shah KR, Kydonieus A, Jamshidi K, Decker SC, Chang T. US Patent
5,527,271; 1996.
[79] Harding KG, Morris HL, Patel GK. BMJ 2002;324:160–3.
[80] Hoare TR, Kohane DS. Polymer 2008;49:1993–2007.
[81] Vashist A, Vashist A, Gupta YK, Ahmad S. J Mater Chem B
2014;2:147.
[82] Elvira C, Mano JF, San Román J, Reis RL. Biomaterials
2002;23:1955–66.
[83] Bierbrauer F. Hydrogel drug delivery: diffusion models. Internal
Report. <www.bierbrauerf.weebly.com>; 2005 [accessed
September 2013].
[84] Peppas NA, Lowman AM. Hydrogels. In: Mathiowitz E, editor.
Encyclopedia of controlled drug delivery. New York: Wiley; 1999.
p. 397–418.
[85] Ende MT, Mikos AG. Pharm Biotechnol 1997;10:139–65.
[86] Gupta P, Vermani K, Garg S. DDT 2002;7:569–79.
[87] Lee PI, Kim CJ. J Control Release 1991;16:229–36.
[88] Ahmed EM. J Adv Res 2013:1–17.
[89] Hamidi M, Azadi A, Raﬁei P. Adv Drug Deliv Rev 2008;60:1638–49.
[90] Bilia A, Carelli V, Di Colo G, Nannipieri E. Int J Pharm
1996;130:83–92.
[91] Cole L, Hanning CD, Robertson S, Quinn K. Brit J Clin Pharmacol
1990;30:781–6.
[92] Karasulu HY, Hilmiog˘lu S, Metin DY, Güneri T. Il Farmaco
2004;59:163–7.
[93] Mandal TK. Eur J Pharm Biopharm 2000;50:337–43.
[94] Hu X, Hao L, Wang H, Yang X, Zhang G, Wang G, et al. Int J Polym Sci
2011;2011:1–9.
[95] Ludwig A. Adv Drug Deliv Rev 2005;57:1595–639.
[96] Rajasekaran A, Arul Kumaran KSG, Padma Preetha J, Karthika K. Int J
Pharmtech Res 2010;2:668–74.
[97] Hornof M, Weyenberg W, Ludwig A, Bernkop-Schnürch A. J Control
Release 2003;89:419–28.
[98] Brazel CS, Peppas NA. J Control Release 1996;39:57–64.
[99] Omidian H, Park K. Superporous hydrogels for drug delivery
systems. In: Siepmann J, Siegel R, Rathbone M, editors.
Fundamentals and applications of controlled release drug
delivery, vol. 4. New York: Springer; 2012. p. 75–106.
[100] Schlegel PN, Kuzma P, Frick J, Farkas A, Gomahr A, Spitz I, et al.
Urology 2001;58:578–82.
[101] Nho Y, Lim Y, An S, Kim Y. EP 1 889 608 B1; 2008.
[102] Soonkap H. Patent application EP 0 524 718 A1; 1993.
[103] Sawhney AS, Jarrett P, Bassett M, Blizzard C. US patent 8,409,606
B2; 2013.
[104] Ocular TherapeutixTM website. <www.ocutx.com> [accessed
November 2014].
[105] Bae YH, Kim SW, Valuev LI. US patent 5,226,902; 1993.
[106] Song SS, Kim HH, Yi YW. US Patent 5,514,380 1996.
[107] Lee SD, Kim BS, Nguyen MK. US Patent 8,383,153 B2; 2013.
[108] Rosenthal A, Barry JJ, Sahatjian R. US Patent 7,066,904 B2; 2006.
[109] Cervidil website. <www.cervidil.com> [accessed September 2013].
[110] Controlled Therapeutics (Scotland) Ltd website.
<www.ctsotland.com> [accessed September 2013].
[111] Endo Pharmaceuticals Solutions Inc. website. <www.endo.com>
[accessed November 2014].
[112] Park K. Biomaterials 1988;9:435–41.
[113] Park K, Chen J, Park H. US Patent 6,271,278 B1; 2001.
[114] Chen J, Blevins WE, Park H, Park K. J Control Release
2000;64:39–51.
[115] Chen J, Park K. J Control Release 2000;65:73–82.
[116] Velasco D, Danoux ChB, Redondo JA, Elvira C, San Román J, Wray PS,
et al. J Control Release 2011;149:140–5.
[117] Bumsang K, Peppas NA. Int J Pharm 2003;266:29–37.
[118] Morishita M, Lowman AM, Takayama K, Nagai T, Peppas NA. J
Control Release 2002;81:25–32.
E. Caló, V.V. Khutoryanskiy / European Polymer Journal 65 (2015) 252–267 267[119] Lowman AM, Morishita M, Nagai T, Peppas NA. US Patent
application WO1998043615 A1; 1998.
[120] Lee KY, Mooney DJ. Chem Rev 2001;101:1869–80.
[121] Chapekar MS. J Biomed Mater Res 2000;53:617–20.
[122] Drury JL, Mooney DJ. Biomaterials 2003;24:4337–51.
[123] Place ES, George JH, Williams CK, Stevens MM. Chem Soc Rev
2009;38:1139–51.
[124] Hunt JA, Chen R, van Veen T, Bryan N. J Mater Chem B
2014;2:5319–38.
[125] Jabbari E, Yaszemski MJ, Currier BL. EP 1 664 168 B1; 2006.
[126] Harris IR, Harmon AM, Brown LJ, Gosiewska A. US Patent 8,039,258
B2; 2011.
[127] Kumar A. US Patent 2013/0236971 A1; 2013.
[128] Blanchard CR, Timmons SF, Smith RA. US Patent 6,379,690 B2;
2002.
[129] Song SK, Jang YM, Jeon IH, Ko SJ, Jeon JR, Chun GT, et al. US Patent
8,592,574 B2; 2013.
[130] Omidian H, Rocca JG, Park K. J Control Release 2005;102:3–12.
[131] Masuda F. Trends in the development of superabsorbent polymers
for diapers. In: Buchholz FL, Peppas NA, editors. Superabsorbent
polymers science and technology, vol. 7. American Chemical
Society Washington; 1994. p. 88–98.
[132] Sannino A, Demitri C, Madaghiele M. Materials
2009;2:353–73.
[133] Brandt KA, Goldman SA, Inglin TA. US Patent Re. 32,649; 1988.
[134] Osborn TW. US Patent 5,009,653; 1991.
[135] Kellenberger ST. US Patent 5,147,343; 1992.
[136] Zohuriaan-Mehr MJ, Kabiri K. Iran Polym J 2008;17:451–77.
Enrica Caló is currently a PhD student in Prof
Khutoryanskiy’s group at Reading School of
Pharmacy, University of Reading (United
Kingdom). Her research project is focused on
the development of polymeric hydrogels for
wound dressing applications. She graduated
from ‘‘La Sapienza’’ University of Rome (Italy)
with Master Degree in Pharmacy in 2012.Vitaliy V. Khutoryanskiy is Professor of For-
mulation Science (since August 2014), having
previously been Associate Professor (Reader)
in Pharmaceutical Materials (2010–2014) and
Lecturer in Pharmaceutics (2005–2010) at
Reading School of Pharmacy, University of
Reading (United Kingdom). Prior to Reading,
he worked as a Research Associate in the
School of Pharmacy and Pharmaceutical Sci-
ences, University of Manchester (2004–2005),
as Research Fellow in the Department of
Pharmaceutical Sciences, University of
Strathclyde (2002–2004) and as a Lecturer in Polymer Chemistry, al-
Farabi Kazakh National University, Kazakhstan (2000–2002). He received
his PhD in polymer chemistry in 2000 from Kazakh National Technical
University (Kazakhstan). Prof Khutoryanskiy has researched broadly in
the area of materials for pharmaceutical and biomedical applications,
with a particular emphasis on mucoadhesive materials, hydrogels and
biomaterials, water-soluble polymers, drug delivery, and stimuli-
responsive polymers. He has published over 100 original research articles,
11 reviews in peer reviewed journals, edited 2 books and ﬁled 2 patent
applications.
